Hennion & Walsh Asset Management, Inc. Vir Biotechnology, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $1.89 Billion
- Q2 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 38,822 shares of VIR stock, worth $300,482. This represents 0.02% of its overall portfolio holdings.
Number of Shares
38,822
Previous 39,150
0.84%
Holding current value
$300,482
Previous $396,000
12.88%
% of portfolio
0.02%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding VIR
# of Institutions
232Shares Held
87.6MCall Options Held
231KPut Options Held
132K-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$129 Million1.37% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$127 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$99.5 Million0.0% of portfolio
-
State Street Corp Boston, MA5.09MShares$39.4 Million0.0% of portfolio
-
Baillie Gifford & CO3.92MShares$30.4 Million0.03% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $1.03B
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...